NM_015450.3:c.1416T>G
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BP4
The NM_015450.3(POT1):c.1416T>G(p.Ser472Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00014 in 1,613,918 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_015450.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POT1 | NM_015450.3 | c.1416T>G | p.Ser472Arg | missense_variant | Exon 15 of 19 | ENST00000357628.8 | NP_056265.2 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000788 AC: 12AN: 152224Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000915 AC: 23AN: 251400Hom.: 0 AF XY: 0.000103 AC XY: 14AN XY: 135878
GnomAD4 exome AF: 0.000146 AC: 214AN: 1461694Hom.: 0 Cov.: 33 AF XY: 0.000143 AC XY: 104AN XY: 727154
GnomAD4 genome AF: 0.0000788 AC: 12AN: 152224Hom.: 0 Cov.: 32 AF XY: 0.0000672 AC XY: 5AN XY: 74366
ClinVar
Submissions by phenotype
Tumor predisposition syndrome 3 Uncertain:2Other:1
This sequence change replaces serine, which is neutral and polar, with arginine, which is basic and polar, at codon 472 of the POT1 protein (p.Ser472Arg). This variant is present in population databases (rs146643991, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with POT1-related conditions. ClinVar contains an entry for this variant (Variation ID: 475044). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt POT1 protein function with a negative predictive value of 80%. RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (internal data). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Variant interpreted as Uncertain significance and reported on 10-26-2020 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -
- -
not specified Uncertain:2
- -
DNA sequence analysis of the POT1 gene demonstrated a sequence change, c.1416T>G, in exon 15 that results in an amino acid change, p.Ser472Arg. This sequence change does not appear to have been previously described in patients with POT1-related disorders. This sequence change has been described in the gnomAD database with a low population frequency of 0.009% (dbSNP rs146643991). The p.Ser472Arg change affects a moderately conserved amino acid residue of the POT1 protein. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Ser472Arg substitution. Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Ser472Arg change remains unknown at this time. -
not provided Uncertain:2
Has not been previously published as pathogenic or benign to our knowledge; In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 28393830) -
To the best of our knowledge, the variant has not been reported in the published literature. The frequency of this variant in the general population, 0.00019 (24/129126 chromosomes in European (Non-Finnish) subpopulation, http://gnomad.broadinstitute.org), is higher than would generally be expected for pathogenic variants in this gene. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Additional analysis using software algorithms for the prediction of the effect of nucleotide changes on POT1 mRNA splicing yielded inconclusive findings . Based on the available information, we are unable to determine the clinical significance of this variant. -
Hereditary cancer-predisposing syndrome Uncertain:1
The p.S472R variant (also known as c.1416T>G), located in coding exon 11 of the POT1 gene, results from a T to G substitution at nucleotide position 1416. The serine at codon 472 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Tumor predisposition syndrome 3;C5830496:Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 8;C5830497:Cerebroretinal microangiopathy with calcifications and cysts 3 Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at